In animal and clinical studies, inhibiting SGLT2 improved GFR and reduced weight gain, kidney fibrosis, and mesangial expansion associated with type 2 diabetes [84–86]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.